Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
In March 2025, CordenPharma signed a multi-year strategic partnership with Viking Therapeutics for GLP-1/GIP drug candidate VK2735 covering peptide API, sterile fill-finish, and oral solid dosage manufacturing
This report delivers comprehensive analysis of GLP-1 market size, competitive dynamics, pipeline innovation, patient access economics, and population health outcomes for 20262035 , covering leading molecules including semaglutide , tirzepatide , liraglutide , orforglipron , and retatrutide
Ask for it in writing before you order
Comparison of the functional properties of trimeric and monomeric CaiT of Escherichia coli
Eli Lilly held approximately 57% of the market as of early 2025, with Novo Nordisk trailing slightly behind as it grapples with supply constraints
The question of whether bacterial GSH-Pxs exhibit similar GSH dependence and how they influence oxidative stress tolerance and pathogenicity in bacteria remains largely unanswered
US$ 28.06
US$ 25.67
US$ 23.21
US$ 23.69
US$ 20.94
